World Prostate Cancer Therapeutics Market Analysed & Forecast by Renub Research in New Report Now Available at MarketPublishers.com
16 Nov 2015 • by Natalie Aster
LONDON – The market for prostate cancer drugs has been evolving at a fast pace in the recent past; and it is poised to nearly double by end-2020, owing to the introduction of innovative, more expensive drugs, advancements in oncology therapeutic domain, and the development in proteomics and genomics. In the prostate cancer therapeutics marketplace, there is significant demand for novel drugs that address unmet needs like increased survival in patients, less toxicity, improved progression-free survival, an upsurge in effectiveness, and also lower costs. The global market keeps on gathering speed, driven mainly by the rise of the hormone–refractory prostate cancer therapeutics sector. However, a number of some hindrances like the high cost of prostate cancer drugs, side effects of treatment as well as low success rates for oncology drugs could pose a challenge to the growth in the prostate cancer market.
Zytiga dominated the prostate cancer drug market as of 2014, followed by Xtandi drugs, Leuplin, Zoladex and Lupron, respectively, in the same year. Bayer's Xofigo, a cancer drug used to treat metastatic castration-resistant prostate cancer, is also boosting its market share. Decapeptyl, Jevtana, Taxotere and Provenge are amid the other cancer drugs in the worldwide market.
New research report “Global Prostate Cancer Therapeutics Market to 2020” elaborated by Renub Research provides a comprehensive analysis of the world prostate cancer therapeutics market. The study sheds light on the driving factors and challenges for the market, gives information on the cancer incidence rates, market share analysis, hormonal therapy drugs sales and forecasts through to 2020. The report presents detailed insights into hemotherapy drugs market, immunotherapy drugs market and targeted therapy drugs market. It presents an extensive examination of the leading market players, as well as an all-round assessment of key drivers and challenges of the prostate cancer therapeutics market.
Global Prostate Cancer Therapeutics Market to 2020
Published: November, 2015
Price: US$ 1,200.00
More new studies by the publisher are available at Renub Research page.